Literature DB >> 26137857

Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid.

Emmerik F A Leijten1, Tessa S van Kempen1, Marianne Boes1, Jocea M R Michels-van Amelsfort1, Dirkjan Hijnen1, Sarita A Y Hartgring1, Joel A G van Roon1, Mark H Wenink1, Timothy R D J Radstake1.   

Abstract

OBJECTIVE: Innate lymphoid cells (ILCs) are a recently discovered group of cells that are essential to epithelial homeostasis and are implicated in psoriasis pathogenesis, yet they have never been reported in psoriatic arthritis (PsA).
METHODS: ILC classes and subsets were characterized in the peripheral blood (PB) of healthy controls, patients with psoriasis, and patients with PsA and in the synovial fluid (SF) of patients with PsA and patients with rheumatoid arthritis (RA). Cell surface marker expression and intracellular cytokine production following stimulation were analyzed using flow cytometry.
RESULTS: ILCs were identified in the SF and were 4-fold more abundant in PsA SF than in PsA PB. Fewer CCR6+ ILCs were found in PsA PB than in healthy control PB, while PsA SF was enriched for CCR6+ ILCs compared to PsA PB and RA SF. Natural cytotoxicity receptor NKp44+ group 3 ILCs were rare in PB and RA SF, but abundant in PsA SF. Increased numbers of interleukin-17A (IL-17A)-producing ILCs were present in PsA SF compared to RA SF. CCR6, NKp44, and melanoma cell adhesion molecule (MCAM) were expressed on the cell surface of SF ILCs that produced IL-17A. The number of circulating NKp44+, CCR6+, and MCAM+ ILCs in blood was inversely correlated with PsA disease activity.
CONCLUSION: Our findings indicate that PsA SF is enriched for group 3 ILCs that express CCR6 and NKp44, which distinguishes the synovial compartment from RA. The increased IL-17A production by SF ILCs indicates a novel role for ILCs in PsA.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26137857     DOI: 10.1002/art.39261

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  28 in total

Review 1.  Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases.

Authors:  Medya M Shikhagaie; Kristine Germar; Suzanne M Bal; Xavier Romero Ros; Hergen Spits
Journal:  Nat Rev Rheumatol       Date:  2017-02-02       Impact factor: 20.543

Review 2.  Innate lymphoid cells: major players in inflammatory diseases.

Authors:  Mikaël Ebbo; Adeline Crinier; Frédéric Vély; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2017-08-14       Impact factor: 53.106

Review 3.  Targeting the interleukin-23/17 axis in axial spondyloarthritis.

Authors:  Ananta Paine; Christopher T Ritchlin
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

Review 4.  ILC3 in Axial Spondyloarthritis: the Gut Angle.

Authors:  Daniele Mauro; Federica Macaluso; Serena Fasano; Riccardo Alessandro; Francesco Ciccia
Journal:  Curr Rheumatol Rep       Date:  2019-06-13       Impact factor: 4.592

Review 5.  Innate lymphoid cells in autoimmunity and chronic inflammatory diseases.

Authors:  Tingting Xiong; Jan-Eric Turner
Journal:  Semin Immunopathol       Date:  2018-03-22       Impact factor: 9.623

6.  Imbalance of Th17, Treg, and helper innate lymphoid cell in the peripheral blood of patients with rheumatoid arthritis.

Authors:  Ting Wang; Jinbing Rui; Wenqi Shan; Fei Xue; Dingqi Feng; Liyang Dong; Jiahui Mao; Yang Shu; Chaoming Mao; Xuefeng Wang
Journal:  Clin Rheumatol       Date:  2022-08-04       Impact factor: 3.650

Review 7.  Psoriatic arthritis: tissue-directed inflammation?

Authors:  Giacomo Cafaro; Iain B McInnes
Journal:  Clin Rheumatol       Date:  2018-02-23       Impact factor: 2.980

Review 8.  Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis.

Authors:  Fabiola Atzeni; Antonio Carriero; Laura Boccassini; Salvatore D'Angelo
Journal:  Immunotargets Ther       Date:  2021-05-03

9.  Aryl hydrocarbon receptor (Ahr)-dependent Il-22 expression by type 3 innate lymphoid cells control of acute joint inflammation.

Authors:  Ramzi Nehmar; Louis Fauconnier; Jose Alves-Filho; Dieudonnée Togbe; Aurore DeCauwer; Seiamak Bahram; Marc Le Bert; Bernhard Ryffel; Philippe Georgel
Journal:  J Cell Mol Med       Date:  2021-03-18       Impact factor: 5.310

10.  Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Authors:  Philip J Mease; Désirée van der Heijde; Christopher T Ritchlin; Masato Okada; Raquel S Cuchacovich; Catherine L Shuler; Chen-Yen Lin; Daniel K Braun; Chin H Lee; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2016-08-23       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.